<DOC>
	<DOCNO>NCT02032277</DOCNO>
	<brief_summary>This 3 arm Phase 3 study evaluate safety efficacy addition veliparib plus carboplatin versus addition carboplatin standard neoadjuvant chemotherapy versus standard neoadjuvant chemotherapy subject early stage TNBC .</brief_summary>
	<brief_title>A Study Evaluating Safety Efficacy Addition ABT-888 Plus Carboplatin Versus Addition Carboplatin Standard Chemotherapy Versus Standard Chemotherapy Subjects With Early Stage Triple Negative Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Triple Negative Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Veliparib</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<criteria>1 . Histologically confirm invasive breast cancer core needle incisional biopsy ( excisional biopsy allow ) . Tumors must clinical stage T23 N02 T1 N12 per AJCC Staging Edition 7 clinical stage T23 N02 T1 N12 physical exam radiologic study . 2 . Documented Breast Cancer Gene ( BRCA ) germline mutation test . 3 . Estrogen Receptor ( ER ) , Progesterone Receptor ( PR ) , Human Epidermal Growth Factor Receptor ( HER ) 2negative ( triplenegative ) cancer breast . 4 . ECOG Performance status 0 1 . 5 . Women must determine childbearing potential ( surgically sterile , postmenopausal define amenorrheic least 12 month ) Investigator OR must negative serum pregnancy test prior randomization . 1 . Previous anticancer treatment ( cytotoxic chemotherapy , immunotherapy , biologic therapy radiotherapy investigational agent ) therapeutic intent current breast cancer . 2 . Previous treatment carboplatin , paclitaxel , doxorubicin , cyclophosphamide Poly ( ADPribose ) Polymerase ( PARP ) inhibitor . 3 . Concurrent treatment ovarian hormonal replacement therapy hormonal agent raloxifene , tamoxifen selective estrogen receptor modulator ( SERM ) . Subjects must discontinue use agent prior begin study treatment . 4 . A history seizure within 12 month prior study entry . 5 . Preexisting neuropathy cause excess Grade 1 .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Oncology</keyword>
	<keyword>United States Oncology - 12152</keyword>
	<keyword>Alliance - AFT-04</keyword>
	<keyword>Triple negative breast cancer</keyword>
	<keyword>National Surgical Adjuvant Breast Bowel Project - B-56-I</keyword>
	<keyword>Grupo Español de Investigación en Cáncer de Mama - GEICAM/2014-02</keyword>
	<keyword>German Breast Group - GBG 81</keyword>
</DOC>